Bristol Myers Squibb stock gains after FDA approval
Published on 08/28/2026 at 06:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock gets a new catalyst after the FDA approved iberdomide, sold as Zenbexus, for relapsed or refractory multiple myeloma on August 28, 2026. The drug carries a list price of $29,500 for a 28-day treatment cycle, and the company expects patients to begin receiving it within weeks.
Why the approval matters
The approval adds another oncology asset to a portfolio that still leans heavily on core treatments such as Eliquis, which generated $2.4 billion in quarterly revenue in the latest reported period cited in recent coverage. That matters because one product line alone is not enough to carry Bristol Myers Squibb's earnings mix.
A separate recent market snapshot put Bristol Myers Squibb at $0.00 per share with a market cap of $0.0 billion, but that figure was not usable for publication because the source set here did not provide a verified stock quote for the company. The more durable story remains the pipeline and the revenue base behind it.
Pipeline and cash flow
Recent coverage also said Pfizer's second-quarter revenue reached $15 billion and that Eliquis, the shared anticoagulant, brought in $2.4 billion in the quarter, up 21% year over year. For Bristol Myers Squibb, that is a reminder that the company still benefits from a large share of revenue tied to established drugs while it pushes new launches forward.
Zenbexus now gives the oncology franchise a dated commercial marker, with the price set at $29,500 per 28-day cycle and first patient access expected within weeks after the August 28, 2026 approval. That creates a concrete near-term focus for investors watching whether the launch can broaden the company's growth profile.
Zenbexus launch watch
Zenbexus is the product name tied to iberdomide in the approval note, and it now becomes the most visible near-term product story for Bristol Myers Squibb. The key test is whether the new therapy can add meaningful volume to a business that still depends on large legacy drugs.
As of August 28, 2026, the latest company-specific market data in the available source set was not presented as a usable quote, so the stock section is kept to the dated catalyst and the commercial price point. The next earnings date was not supplied in a source-backed form that could be used here.
More on Bristol Myers Squibb
Company: Bristol Myers Squibb Company
ISIN: US0897961004
Ticker: BMY
Exchange: NYSE
Sector / Industry: Health Care / Pharmaceuticals
Index membership: S&P 500
Share price context
Bristol Myers Squibb shares trade on the NYSE under BMY. The company remains a large U.S. pharmaceutical name with oncology, immunology, cardiovascular, and hematology exposure.
Investor Relations
More on Bristol Myers Squibb stock and its pipeline can be found through the company's investor materials.
